File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

TitleA staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
Authors
Issue Date2010
PublisherFondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org
Citation
The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 How to Cite?
Abstract
Bortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities.
DescriptionHaematologica is supplement of the Hematology Journal
Persistent Identifierhttp://hdl.handle.net/10722/126416
ISSN
2013 Impact Factor: 5.868

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorChan, EYTen_HK
dc.contributor.authorLeung, YYen_HK
dc.contributor.authorCheung, SCW-
dc.contributor.authorChan, SYT-
dc.contributor.authorLiang, R-
dc.contributor.authorKwong, YL-
dc.date.accessioned2010-10-31T12:27:23Z-
dc.date.available2010-10-31T12:27:23Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489en_HK
dc.identifier.issn0390-6078en_HK
dc.identifier.urihttp://hdl.handle.net/10722/126416-
dc.descriptionHaematologica is supplement of the Hematology Journal-
dc.descriptionThis journal supplement is Abstract Book of 15th EHA 2010-
dc.description.abstractBortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities.-
dc.languageengen_HK
dc.publisherFondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org-
dc.relation.ispartofHaematologica: the Hematology Journal-
dc.titleA staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myelomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChim, CS: jcschim@hku.hken_HK
dc.identifier.emailLie, AKW: akwlie@hkucc.hku.hken_HK
dc.identifier.emailChan, EYT: eytchan@hkucc.hku.hken_HK
dc.identifier.emailCheung, SCW: ccwsteph@hku.hk-
dc.identifier.emailLiang, R: rliang@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hku.hk-
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros172211en_HK
dc.identifier.volume95-
dc.identifier.issues2-
dc.identifier.spage593-
dc.identifier.epage593-
dc.publisher.placeItaly-
dc.description.otherThe 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats